Radiotherapy (miBG) in neuroblastoma combined with chemotherapy (talazoparib)
This study, called MINT, is for children and young people over one year old who have neuroblastoma that has come back or hasn't responded to initial treatments. Neuroblastoma is a type of childhood cancer. The study combines a special radiation treatment called 131I-mIBG with a chemotherapy drug called talazoparib. Researchers want to see if talazoparib helps the radiation work better by making cancer cells more sensitive to it. They will also look at whether certain changes in a patient's genes affect how well this treatment works. The information gained will help improve future treatments for neuroblastoma.
En un coup d'œil
De quoi parle cette étude ?
The MINT study is a medical research project looking for better ways to treat a type of cancer called neuroblastoma in children and young adults. Neuroblastoma is the most common solid tumour found outside the brain in children, and it can be very serious. Sadly, for many children, the cancer either doesn't respond to the first treatments or comes back after treatment. This is what doctors call "relapsed or refractory" neuroblastoma.
Currently, a treatment called 131I-mIBG therapy is used. This is a special type of radiation that targets the cancer cells. However, it doesn't always work for everyone. In this study, doctors are combining this radiation therapy with a drug called talazoparib. This drug belongs to a group called PARP inhibitors. Lab studies have shown that PARP inhibitors can make cancer cells more sensitive to radiation, meaning the radiation might work better. We want to see if this combination of 131I-mIBG and talazoparib is more effective at treating neuroblastoma.
We are also interested in how a patient's genes might play a role. Some neuroblastoma cells have specific gene changes that make it harder for them to fix damage to their DNA. We think that talazoparib might be particularly helpful for these patients. By taking part in this study, you would be helping us learn more about how to fight neuroblastoma, which could lead to improved treatments for children in the future.
Points clés
- This study is for children and young adults with high-risk neuroblastoma that has returned or hasn't responded to previous treatment.
- It tests a new combination treatment: targeted radiation (131I-mIBG) plus a drug (talazoparib).
- The aim is to see if this combination works better, especially for those with specific gene changes.
- Participation involves one course of treatment, a stem cell rescue, and at least two years of follow-up.
- Potential benefits include better treatment, but there are risks from the treatments and extra tests.
- The study helps improve future neuroblastoma treatments.
Qui peut être éligible ?
To be considered for this study, patients must be older than one year of age and have been diagnosed with high-risk neuroblastoma that has either returned or hasn't improved with previous treatments.
Your medical team will need to confirm that scans show your neuroblastoma is still active and that you have enough healthy stem cells available for a special procedure after treatment. They will also check your general health and how well you can do daily activities. You will need to have some previous treatment information or a recent genetic test report available for the study doctors to review.
There are also some requirements about when your last treatments were. For example, you must have finished certain chemotherapies at least two weeks before joining the study, and radiation therapy at least two weeks beforehand. Your doctor will carefully review all your medical information to see if this study is right for you.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Are you over one year old?
- Do you have high-risk neuroblastoma that has come back or hasn't responded to other treatments?
- Do scans show that your neuroblastoma is still active and can be targeted by the 131I-mIBG treatment?
- Do you have enough healthy stem cells available for a stem cell rescue?
- Are you generally well enough to take part, as assessed by your doctor?
- Have you finished any previous treatments within the required timeframe before joining?
En quoi consiste la participation ?
If you join the study, you will receive two treatments: the drug talazoparib and the targeted radiation therapy 131I-mIBG. Doctors will closely monitor your reaction to these treatments. You will receive one course of this combined treatment. After that, you will have a special procedure called a stem cell rescue, which helps your body recover from the treatment.
During your time in the study, you will have regular visits with the medical team. This will involve physical examinations, blood tests, and imaging scans (like X-rays or MRI scans) to see how you are responding to the treatment and to check for any side effects. Some blood tests might be taken at the same time as your routine blood tests to minimise any discomfort. You will be followed up for at least two years after your treatment to keep track of your health and the long-term effects of the treatment.
Risques et avantages potentiels
Emplacements (6)
- L'Hôpital Royal MarsdenApproximatifLondres, Royaume-Uni
- Royal Hospital for Sick Children (Glasgow)ApproximatifGlasgow, Royaume-Uni
- UclhApproximatifLondres, Royaume-Uni
- Hospital for Sick ChildrenApproximatifToronto, Canada
- Princess Máxima Center for Pediatric OncologyVille uniquementUtrecht, Pays-Bas
- Charité Universitätsmedizin BerlinApproximatifBerlin, Allemagne
Questions fréquentes
What is neuroblastoma?
Neuroblastoma is a type of cancer that usually affects children and young adults, often developing in nerve tissue outside of the brain.
What is I-131-mIBG therapy?
This is a special treatment that uses a mild radioactive substance, 131I-mIBG, that targets and delivers radiation directly to neuroblastoma cells.
What is talazoparib?
Talazoparib is a drug that might make neuroblastoma cells more sensitive to radiation therapy, potentially making the treatment more effective.
Will I have more tests if I join this study?
Yes, you will likely have more blood tests and imaging scans (like X-rays or MRI) to help doctors understand how the treatment is working.
Where is this study taking place?
The study is based out of the University of Birmingham in the UK, but patients from different locations may be able to participate.
Comment en savoir plus
Catherine Cochrane
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.